Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-2511PMID 17545538
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

  2009cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.

  2006cited by this paper
• Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

  2006cited by this paper
• Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

  2006cited by this paper
• Characterization of familial Waldenstrom's Macroglobulinemia.

  2006cited by this paper
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  2006cited by this paper
• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  2006cited by this paper
• Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

  2006cited by this paper
• Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

  2006cited by this paper
• Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

  2006cited by this paper
• Peripheral neuropathies in Waldenström’s macroglobulinaemia

  2006cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• Diagnosis and management of Waldenstrom's macroglobulinemia.

  2005cited by this paper
• Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study

  2005cited by this paper
• Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

  2005cited by this paper
• PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

  2005cited by this paper
• Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study.

  2004cited by this paper
• Amyloidosis and Waldenström's macroglobulinemia.

  2004cited by this paper
• Characterization of familial Waldenstrom's macroglobulinemia.

  2004cited by this paper
• Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.

  2004cited by this paper
• A role for the unfolded protein response in optimizing antibody secretion.

  2004cited by this paper
• Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

  2002cited by this paper
• World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

  1999cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper

• Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.

  2025cites this paper
• Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

  2025cites this paper
• Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

  2024cites this paper
• Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Optimizing BTK Inhibition in Waldenström Macroglobulinemia.

  2024cites this paper
• Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia

  2023cites this paper
• Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia.

  2023cites this paper
• The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.

  2023cites this paper
• Negligible role of TRAIL death receptors in cell death upon endoplasmic reticulum stress in B-cell malignancies

  2023cites this paper
• Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

  2023cites this paper
• Current approach to Waldenström macroglobulinemia.

  2023cites this paper
• A rare case report of waldenström macroglobulinemia converted to serum low IgM

  2023cites this paper
• Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

  2023cites this paper
• Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience

  2022cites this paper
• A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia

  2022cites this paper
• Current approach to Waldenström Macroglobulinemia.

  2022cites this paper
• Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia

  2022cites this paper
• Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

  2022cites this paper
• Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First

  2022influential citation
• Managing Waldenström’s macroglobulinemia with BTK inhibitors

  2022cites this paper
• IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

  2022cites this paper
• Treatment of relapsed and refractory Waldenstrom Macroglobulinemia

  2022cites this paper
• Reducing treatment toxicity in Waldenström macroglobulinemia

  2021cites this paper
• Protein clearance strategies for disease intervention

  2021cites this paper
• Managing complications secondary to Waldenström’s macroglobulinemia

  2021cites this paper
• Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

  2020cites this paper
• A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia

  2020cites this paper
• An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia

  2020cites this paper
• Current and Emerging Treatments for Waldenström Macroglobulinemia

  2020cites this paper
• Waldenstrom's macroglobulinemia in the era of immunotherapy

  2020cites this paper
• Zanubrutinib for the treatment of Waldenström Macroglobulinemia

  2020cites this paper
• Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma.

  2020cites this paper
• Current Therapeutic Options in Waldenström Macroglobulinemia Management of peripheral neuropathy in Waldenström macroglobulinemia

  2019cites this paper
• Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

  2019cites this paper
• Current Therapeutic Options in Waldenström Macroglobulinemia

  2019cites this paper
• New drug therapies to kill TSC2-deficient cell lines

  2019cites this paper
• JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia (LPL/WM)

  2019cites this paper
• How I treat Waldenström's Macroglobulinemia.

  2019cites this paper
• Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cites this paper
• First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.

  2018cites this paper
• Proteasome Inhibitors in Waldenström Macroglobulinemia.

  2018cites this paper
• Cancer Neurology in Clinical Practice

  2018cites this paper
• Neurological Complications of Chemotherapy

  2018cites this paper
• A safety profile of medications used to treat Waldenström’s macroglobulinemia

  2018influential citation
• Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

  2018cites this paper
• BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

  2017cites this paper
• Genetic and Signaling Abnormalities in Waldenstrom’s Macroglobulinemia

  2017cites this paper
• Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

  2017cites this paper
• Waldenström Macroglobulinemia: Review of Pathogenesis and Management

  2017influential citation
• A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone

  2017influential citation
• Immunomodulatory Agents and Proteasome Inhibitors in Waldenstrom’s Macroglobulinemia

  2017cites this paper
• The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions

  2017cites this paper
• Response Assessment in Waldenström’s Macroglobulinaemia

  2017cites this paper
• Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

  2017cites this paper
• Caracterización molecular de la macroglobulinemia de waldenström: implicaciones en el diagnóstico, pronóstico y transformación histológica

  2017cites this paper
• Waldenström’s Macroglobulinemia Immunophenotype

  2017cites this paper
• Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment

  2017cites this paper
• Low‐dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia

  2017cites this paper
• Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

  2017cites this paper
• The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

  2017cites this paper
• Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

  2017cites this paper
• Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.

  2016cites this paper
• Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

  2016cites this paper
• Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells

  2016cites this paper
• Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

  2016cites this paper
• Novel therapeutic targets in Waldenstrom macroglobulinemia.

  2016cites this paper
• The role of stem cell transplantation in Waldenstrom's macroglobulinemia.

  2016cites this paper
• Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

  2016cites this paper
• Current therapy guidelines for Waldenstrom's macroglobulinaemia.

  2016cites this paper
• Future therapeutic options for patients with Waldenström macroglobulinemia.

  2016cites this paper
• Waldenström macroglobulinemia: biology, genetics, and therapy

  2016cites this paper
• Proteasome Inhibitor Bortezomib: A Double-Edged Sword in CancerTherapy

  2016cites this paper
• Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

  2015cites this paper
• Phase II clinical trials for Waldenstrom’s macroglobulinemia

  2015cites this paper
• Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

  2015cites this paper
• Waldenstrom macroglobulinemia: prognosis and management

  2015cites this paper
• Biology, prognosis, and therapy of Waldenström Macroglobulinemia.

  2015cites this paper
• Waldenström’s macroglobulinaemia : Belgian Hematology Society guidelines

  2015cites this paper
• Waldenström macroglobulinemia.

  2015cites this paper
• Ibrutinib for the treatment of Waldenström macroglobulinemia

  2015cites this paper
• Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

  2015influential citation
• Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

  2015cites this paper
• Waldenström macroglobulinemia: What a hematologist needs to know.

  2015cites this paper
• How I treat Waldenstr¨ om macroglobulinemia

  2015cites this paper
• Guidelines on the diagnosis and management of Waldenström macroglobulinaemia

  2014cites this paper
• Current and future therapeutic approach for Waldenström's macroglobulinemia.

  2014cites this paper
• macroglobulinemia neuropathy-sparing approach for treating Waldenström's Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a

  2014cites this paper
• Waldenström macroglobulinemia at 70

  2014cites this paper
• Waldenstrom’s Macroglobulinemia

  2014cites this paper
• Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.

  2014cites this paper
• Waldenström macroglobulinemia.

  2014cites this paper
• Overview on clinical trials in Waldenstrom's macroglobulinemia

  2014cites this paper
• Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

  2014cites this paper
• The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases

  2014cites this paper
• Maladie de Waldenström ou macroglobulinémie

  2014cites this paper
• macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström

  2014cites this paper
• Avant propos et préface

  2014cites this paper
• Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

  2014cites this paper
• Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.

  2014cites this paper
• Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

  2014cites this paper